Skip to main content

Table 2 Exposure to the different biologic response modifiers depending on diagnosis in BIOBADASER

From: Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER

Diagnosis Infliximab Etanercept Adalimumab
Rheumatoid arthritis 5,521 (840) 1,724 (188) 526 (67)
All spondylarthritis 1,915 (211) 507 (35) 5.7 (3)
   Ankylosing spondylitis 873 (87) 134 (13) 0.8 (0)
   Psoriatic arthritis 636 (84) 325 (16) 2.6 (2)
   Undifferentiated spondylarthritis 257 (28) 35 (4) 1.4 (0)
   Crohn's related spondylarthritis 124 (9) 2.8 (0) 0.7 (0)
   Other spondylarthritis 22 (3) 9.5 (2) 0.3 (1)
  1. Numbers indicate total patient-years. In parentheses are the numbers of treatments discontinued.